SCHEMBL454528

SCHEMBL454528

[CH2]CC[CH]c1ccccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
KMT2A Q03164 2/20 0.54
ATM Q13315 1/20 0.54
NR4A1 P22736 1/20 0.42
MAOA P21397 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
GRM4 Q14833 1/20 0.39
G6PC1 P35575 1/20 0.39
ALDH1A1 P00352 1/20 0.38
PKM P14618 1/20 0.38
USP2 O75604 1/20 0.38
IKBKB O14920 2/20 0.37
RAF1 P04049 2/20 0.37
RPS6KB1 P23443 2/20 0.37
MAPK1 P28482 2/20 0.37
AKT1 P31749 2/20 0.37
AKT2 P31751 2/20 0.37
KDR P35968 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL96245 0.79 MEN1 (0.54) MEN1NPC1RAB9AKMT2AATM
SCHEMBL8200557 0.79 MEN1 (0.48) MEN1NPC1RAB9AKMT2AATM
SCHEMBL3909700 0.78 MEN1 (0.52) MEN1NPC1RAB9AKMT2AATM
SCHEMBL4651571 0.77 MEN1 (0.56) MEN1NPC1RAB9AKMT2AATM
SCHEMBL8552227 0.76 HRH1 (0.52) MEN1NPC1RAB9AKMT2AATM
SCHEMBL498505 0.76 NPC1 (0.50) MEN1NPC1RAB9AKMT2AATM
SCHEMBL946754 0.76 NPC1 (0.50) MEN1NPC1RAB9AKMT2AATM
SCHEMBL270008 0.76
SCHEMBL498600 0.75 CYP1A2 (0.50) MEN1NPC1RAB9AKMT2AATM
SCHEMBL947177 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0683174-B1 Thioether containing photopolymerizable compositions EASTMAN KODAK CO (US) 1998-08-05 EP claimed
US-5532286-A BONDING STRENGTH EASTMAN KODAK COMPANY (US) 1996-07-02 US claimed
US-5518789-A ACRYLIC ESTER OR AMIDE, OPTICAL RECORDING EASTMAN KODAK COMPANY (US) 1996-05-21 US claimed
EP-0683174-A2 Thioether containing photopolymerizable compositions EASTMAN KODAK COMPANY (US) 1995-11-22 EP claimed
US-11712485-B2 Triazine based radiopharmaceuticals and radioimaging agents MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2023-08-01 US disclosed
US-11389464-B2 Arginase inhibitors as therapeutics MARS, INCORPORATED (US) 2022-07-19 US disclosed
EP-3939972-A1 TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS Molecular Insight Pharmaceuticals, Inc. (US) 2022-01-19 EP disclosed
US-20210338850-A1 TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2021-11-04 US disclosed
EP-3545978-B1 TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS MOLECULAR INSIGHT PHARM INC (US) 2021-09-08 EP disclosed
US-10898598-B2 Triazine based radiopharmaceuticals and radioimaging agents MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2021-01-26 US disclosed
EP-3719024-A1 ARGINASE INHIBITORS AS THERAPEUTICS Mars, Incorporated (US) 2020-10-07 EP disclosed
US-20200246362-A1 Arginase Inhibitors as Therapeutics MARS, INCORPORATED 2020-08-06 US disclosed
WO-2012058065-A1 BORONATES AS ARGINASE INHIBITORS MARS INCORPORATED (US) 2012-05-03 WO disclosed
US-20120083469-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2012-04-05 US disclosed
WO-2012033525-A2 P53-MDM2 ANTAGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-03-15 WO disclosed
WO-2011133653-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED (US) 2011-10-27 WO disclosed
EP-0683174-B1 Thioether containing photopolymerizable compositions EASTMAN KODAK CO (US) 1998-08-05 EP disclosed
US-5532286-A BONDING STRENGTH EASTMAN KODAK COMPANY (US) 1996-07-02 US disclosed
US-5518789-A ACRYLIC ESTER OR AMIDE, OPTICAL RECORDING EASTMAN KODAK COMPANY (US) 1996-05-21 US disclosed
EP-0683174-A2 Thioether containing photopolymerizable compositions EASTMAN KODAK COMPANY (US) 1995-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11389464-B2 Arginase inhibitors as therapeutics ARG1, ARG2, PRMT1 MEN1 3256/4885NPC1 1758/4885RAB9A 1827/4885
US-20210338850-A1 TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS PSMA2, PSMA5, PSMA1 MEN1 104/4885NPC1 1344/4885RAB9A 1942/4885
US-10898598-B2 Triazine based radiopharmaceuticals and radioimaging agents PSMA2, PSMA5, PSMA1 MEN1 104/4885NPC1 1344/4885RAB9A 1942/4885
US-11712485-B2 Triazine based radiopharmaceuticals and radioimaging agents PSMA2, PSMA5, PSMA1 MEN1 104/4885NPC1 1344/4885RAB9A 1942/4885
US-20200246362-A1 Arginase Inhibitors as Therapeutics ARG1, ARG2, PRMT1 MEN1 3256/4885NPC1 1758/4885RAB9A 1827/4885
US-20120083469-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 MEN1 2806/4885NPC1 2297/4885RAB9A 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.